Biotech stocks had already been gaining ground before this week’s news. In June, the iShares Nasdaq Biotechnology ETF (IBB) ...

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the ...

BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

European regulators have officially approved the latest 2026–2027 COVID-19 vaccine formula from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Designed to protect against the widespread XFG ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...